• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 3. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 4. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 5. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804

Introduction to (+-)-(3ac,7ac)-Octahydro-4r,7c-Methano-Inden-5-One Oxime (CAS No. 6319-15-9)

Chemical compounds play a pivotal role in the advancement of pharmaceutical research and development. Among these, (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime, identified by its CAS number 6319-15-9, has garnered significant attention due to its unique structural and functional properties. This compound, characterized by its complex heterocyclic framework and oxime functional group, exhibits promising potential in various biochemical applications.

The molecular structure of (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime consists of an octahydroindenone core substituted with acetyl groups at the 3 and 7 positions, further modified by an oxime moiety at the 5 position. This intricate arrangement contributes to its distinctive chemical reactivity and biological activity. The presence of the oxime group (–NOH) not only influences its solubility and stability but also enhances its interaction with biological targets, making it a valuable candidate for drug design.

In recent years, there has been a surge in research focused on developing novel heterocyclic compounds with potential therapeutic applications. (+-)-(3ac,7ac)-Octahydro-4r,7c-methano-inden-5-one oxime has emerged as a compound of interest in this domain due to its ability to modulate various biological pathways. Studies have demonstrated its efficacy in inhibiting certain enzymes and receptors that are implicated in inflammatory and neurodegenerative diseases. The compound's dual functionality, arising from the combination of the octahydroindenone scaffold and the oxime group, allows for selective binding to target molecules, thereby minimizing off-target effects.

One of the most compelling aspects of (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime is its synthetic versatility. The acetyl groups at the 3 and 7 positions provide numerous opportunities for further chemical modifications, enabling researchers to tailor the compound's properties for specific applications. This flexibility has led to the development of several derivatives that exhibit enhanced bioavailability and improved pharmacokinetic profiles. Such modifications are crucial for translating laboratory findings into viable clinical candidates.

The oxime functional group is particularly noteworthy for its role in enhancing the compound's interaction with biological systems. Oximes are known for their ability to chelate metal ions and form stable complexes with various biomolecules. This property has been exploited in the design of metal-based therapeutics and in the development of agents that target metalloenzymes involved in disease processes. In the context of (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime, the oxime group may serve as a ligand for metal ions or participate in hydrogen bonding interactions with nucleophilic residues on protein targets.

Recent advancements in computational chemistry have further facilitated the exploration of (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime's potential applications. Molecular modeling studies have provided insights into its binding affinity and mode of action at various biological targets. These simulations have helped identify key structural features that contribute to its activity, guiding the optimization of lead compounds for clinical development. The integration of experimental data with computational predictions has accelerated the discovery process and enhanced our understanding of this compound's mechanism of action.

The pharmacological profile of (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime has been extensively evaluated through both in vitro and in vivo studies. Preclinical trials have revealed promising results regarding its efficacy in models of inflammation and neurodegeneration. The compound's ability to modulate key signaling pathways associated with these diseases suggests its potential as a therapeutic agent. Furthermore, its favorable pharmacokinetic properties, including good solubility and moderate metabolic stability, make it an attractive candidate for further development.

The synthesis of (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime involves multi-step organic transformations that highlight the expertise required in medicinal chemistry. The process typically begins with the construction of the octahydroindenone core through cyclization reactions followed by functionalization at specific positions using acetylating agents. The introduction of the oxime group is achieved through condensation reactions with appropriate aldehydes or ketones under controlled conditions. Each step requires careful optimization to ensure high yield and purity.

The stereochemistry of (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime is another critical aspect that influences its biological activity. The presence of chiral centers at the 4r and 7c positions necessitates careful control during synthesis to obtain the desired enantiomer or enantiomeric mixture. Advances in asymmetric synthesis have enabled researchers to produce enantiomerically pure forms of this compound, which are often more effective and less toxic than racemic mixtures.

In conclusion, (+-)-(3ac,7ac)-octahydro-4r,7c-methano-inden-5-one oxime (CAS No. 6319-15-9) represents a significant advancement in pharmaceutical research due to its unique structural features and promising biological activities. Its complex heterocyclic framework combined with the presence of an oxime group makes it a versatile tool for drug discovery. Ongoing studies continue to uncover new applications for this compound，underscoring its importance in addressing various diseases.

• 2792-42-9((1R)-Camphor Oxime)
• 193089-03-1(Bicyclo[2.2.1]heptan-2-one,7,7-dimethyl-, oxime, (2E)-)
• 37939-80-3(N-{1,7,7-trimethylbicyclo2.2.1heptan-2-ylidene}hydroxylamine)
• 13559-66-5(1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one oxime)
• 802917-50-6(Bicyclo[2.2.1]heptan-2-one,1-ethyl-, oxime, (1S,4R)-)
• 36065-15-3(Bicyclo[2.2.1]heptan-2-one,1,7,7-trimethyl-, oxime, (1S,4S)-)
• 31483-97-3(Bicyclo[3.2.1]octan-2-one, oxime)
• 75147-23-8(Bicyclo[3.2.1]octan-8-one,1,5-dimethyl-, oxime)
• 1035-62-7(Androstan-17-one,oxime, (5a)- (9CI))
• 66050-55-3((ne)-n-(1,2,3,3a,5,6,7,7a-octahydroinden-4-ylidene)hydroxylamine)